Google’s Latest Partnership Could Revolutionize Genome Analysis!

On Wednesday, Google (NASDAQ: GOOGL) quietly added an 800-pound gorilla to its arsenal.

Google Genomics, the company’s cloud-computing platform for life science research, added a tool called the Genome Analysis Toolkit (or GATK), which was developed by the Broad Institute of MIT and Harvard.

This amazing piece of software will help scientists quickly analyze genome-sequencing data. Before, this information was sectioned off in academic labs across the country. But as a service, it’s now online for academic researchers to use for free.

The best part however isn’t the accessibility, but all the possibilities that partnering with Google will offer.

The Genome Analysis Toolkit will now run on Google’s very powerful cloud-computing infrastructure, giving it the horsepower it needs to crunch the massive data sets of human genomic data — fast.

Sequencing human DNA generates colossal amounts of data. It’s like 100 gigabytes per person. The basic model for iPhone 6 only has 16! So for researchers, this is big news!

To date, the Broad Institute has either sequenced or genotyped the equivalent of more than 1.4 million biological samples. That’s a whole lot of data to have readily accessible! With the Google partnership, the Institute can now focus on its research without having to worry about managing IT infrastructure.

This trend in outsourcing the infrastructure of DNA processing is picking up across the biotech industry. Besides Google, there are several other companies starting to make a splash in this arena.

For my BioTech Intel Trader readers, that means opportunities to profit from the market plays behind this igniting industry… and many others in the health and biotech sectors.

You can get in on the action here.

Image Signature

Ben Benoy
Editor, BioTech Intel Trader

Why Winners Keep Winning (And Losers Keep Losing)

If “buy-and-hold” and the notion that you can’t beat the market have left you short of your personal and retirement goals, then you’re going to want to hear the truth about passive and active investing.

Chances are, if you’re more than 25 years old, you think it’s impossible to “beat the market!”

But today, there is MORE than ample evidence that proves:

  • The stock market is NOT perfectly efficient
  • Passive investing can be MORE risky than active investing

You CAN beat the market… you just need to use the right strategy!

Get your FREE copy of the latest report from Adam O’Dell, Why Winners Keep Winning (And Losers Keep Losing)

Click to Learn More
Categories: Biotech

About Author

Ben Benoy is a veteran of the U.S. Marine Corps and has been an active retail trader since 2006. He identifies investment opportunities based on key social media trends. He first identified the concept in 2008 and has since developed a tool for tracking investment “chatter” between social media users. His proprietary Social Media Stock Sentiment system has developed into a state-of-the-art platform that identifies and classifies chatter about stocks through algorithms and other indicators to forecast stock-price direction. Ben’s track record speaks for itself — over the past 12 months, his system boasts a win rate of 82.2% on 112 stock trades.